Date: 2015-12-01
Type of information: Licensing agreement
Compound: allogeneic T-cell therapies
Company: Adaptimmune (UK) Universal Cells (USA - PA)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration licensing development
Action mechanism: cell therapy
Disease:
Details: * On December 1, 2015, Adaptimmune and Universal Cells, a genome editing company developing universal donor stem cells, announced that they have entered into a collaboration and exclusive license agreement for the development of allogeneic T-cell therapies. With Universal Cells’ proprietary gene editing technology, Adaptimmune intends to develop affinity enhanced donor T-cells that are universally applicable. The enhanced T-cell technology involves selective engineering of cell surface proteins (TCRs and class I and class II HLA proteins), without the use of nucleases, to develop universal T-cell products. Adaptimmune and Universal Cells are planning to develop these off the-shelf allogeneic affinity-enhanced T-cell therapeutics to treat large patient populations. Under the terms of the agreement, Universal Cells will grant to Adaptimmune an exclusive, sub-licensable, worldwide license to use, sell, supply, manufacture, import, and develop products and services utilizing Universal Cells’ technology within the T-cell immunotherapy field.
Financial terms: Universal Cells will receive an upfront license and start-up fee of $5.5 million, and will be eligible for up to $41 million in milestone payments for certain development and product milestones. Universal Cells would also receive a profit-share payment for the first product, and royalties on sales of other products utilizing its technology.
Latest news:
